Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

NCT05860296 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

36

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy and enrollment challenges

Conditions

Lung Cancer, Nonsmall Cell
Lung Cancer Stage IV
Lung Cancer Metastatic

Interventions

DRUG: SLC-391
BIOLOGICAL: pembrolizumab

Sponsor

SignalChem Lifesciences Corporation

Collaborators

[object Object]